Publications by authors named "S Racadot"

Purpose: Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative radiation therapy (SABR). Evidence to support this paradigm is scarce in squamous cell carcinoma of the head and neck (HNSCC). The multicenter open-label randomized GORTEC 2014-04 (NCT03070366) phase 2 study assesses survival without definitive quality of life (QoL) deterioration of omitting upfront chemotherapy in oligometastatic patients with HNSCC using SABR alone, in the French Head and Neck Intergroup.

View Article and Find Full Text PDF

Unlabelled: The EORTC 22922/10925 trial aimed to investigate the impact on overall survival (OS) of elective internal mammary and medial supraclavicular (IM-MS) radiation therapy (RT) in breast cancer stage I-III. Surgery for the primary tumour and axillary lymph nodes, chest wall RT, boost RT after whole breast RT in breast conserving therapy (BCT), RT to operated axilla, and systemic therapy were per physician's preference. The aim of the current analysis is to assess breast cancer outcomes according to different locoregional and systemic therapy used in the trial.

View Article and Find Full Text PDF

In this article, we propose a consensus delineation of postoperative clinical target volumes for the primary tumour in maxillary sinus and nasal cavity cancers. These guidelines are developed based on radioanatomy and the natural history of those cancers. They require the fusion of the planning CT with preoperative imaging for accurate positioning of the initial GTV and the combined use of the geometric and anatomical concepts for the delineation of clinical target volume for the primary tumour.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the combination of atezolizumab (a PD-L1 inhibitor) and stereotactic body radiation therapy (SBRT) in patients with advanced colorectal cancer (CRC) as part of the SABR-PDL1 trial.
  • A group of 60 pretreated patients from five centers participated, receiving atezolizumab and follow-up SBRT, with a focus on measuring progression-free survival (PFS) and collecting immune profiling data.
  • Results showed a median overall survival of 8.4 months and a PFS of 1.4 months, with the treatment being relatively well-tolerated; some patients exhibited significant responses, including stable disease and a few partial or
View Article and Find Full Text PDF

Purpose: To investigate the performance of 4 atlas-based (multi-ABAS) and 2 deep learning (DL) solutions for head-and-neck (HN) elective nodes (CTVn) automatic segmentation (AS) on CT images.

Material And Methods: Bilateral CTVn levels of 69 HN cancer patients were delineated on contrast-enhanced planning CT. Ten and 49 patients were used for atlas library and for training a mono-centric DL model, respectively.

View Article and Find Full Text PDF